AlgenScribe Raises €470K to Advance Next-Generation Genome Editing Platform and Expand Scientific Collaborations
AlgenScribe, a French biotechnology startup developing a next‑generation genome editing platform designed to improve human health by addressing key limitations in existing gene replacement technologies, has successfully raised €470,000 in equity financing to support the ongoing development of its innovative molecular biology tools and expand its scientific collaborations. The funding marks a major milestone for the company as it pushes forward from early‑stage research toward translational applications with the potential to impact gene therapy, diagnostics and bioproduction.
Founded in 2022 with operations in Nice and Saclay, France, AlgenScribe aims to unlock new possibilities in genome editing by combining multiple synergistic molecular tools into a unified platform. The company’s technology is engineered to accurately edit pathogenic DNA — from base‑level changes to large gene replacements — with improved efficiency and cell viability compared with conventional approaches. This adaptability could broaden gene therapy’s reach across a range of genetic diseases and clinical contexts.
The €470,000 equity financing round brings not only capital but also increased external validation for AlgenScribe’s platform, which integrates advanced molecular biology strategies to overcome barriers in homologous recombination and other key editing processes. Alongside the financing, the company has signed its first collaboration with an American foundation, underscoring its growing international footprint and commitment to expanding its scientific network.
AlgenScribe’s funding round included support from a range of institutional, regional and innovation‑centric backers that have been involved in the company’s evolution since its inception. Participation came from organisations instrumental to its early growth and ecosystem support, including Provence Côte d’Azur (PCA) incubator and Région Sud, both of which helped anchor the company within the vibrant biotechnology cluster in Nice. These regional partners have played a formative role in facilitating AlgenScribe’s development environment.
The company has also been supported by Bpifrance, France’s national public investment bank that backs youthful technology companies with potential for scientific and economic impact. Bpifrance’s support aligns with its mandate to accelerate innovative ventures in deeptech and life sciences. Additionally, YES Invest (Yvelines Essonne Saclay Invest) participated in earlier investment activity, bringing early‑stage capital from a syndicate of business angels that helped fuel initial research and operational setup.
A significant part of AlgenScribe’s financing to date has also come through grant support and collaborative research funding, including a three‑year grant from the Agence Nationale de la Recherche secured in collaboration with the Institut Imagine, a leading European research institute focused on genetic disease study and therapy development. This partnership has contributed to foundational preclinical work and helped advance proof‑of‑concept studies for rare disease applications of the technology.
The €470,000 raised will be deployed primarily to continue platform development, bolster laboratory capacity at its Nice and Saclay facilities, and support additional preclinical research efforts. AlgenScribe plans to pursue ex vivo applications of its tools in collaboration with academic and industry partners as it moves toward broader therapeutic demonstration studies expected in 2026 and beyond.
Looking ahead, the company anticipates launching a larger funding round in late 2026 or early 2027 to fuel downstream efforts, including proof‑of‑concept work in patient‑derived cells and small animal disease models. Such milestones are viewed as critical steps on the path to translational impact and commercialization in the gene therapy space.
AlgenScribe’s journey includes earlier pre‑seed activity, such as its first pre‑seed round in mid‑2023, backed by YES Invest business angels, which helped initiate research and early proof‑of‑concept work on multiple disease targets. Those early funds, combined with the recent equity financing and grant support, have collectively provided about €1 million in capital since the company’s founding.
The startup’s strategy emphasizes strategic collaborations, both academic and industrial, to accelerate research and broaden application domains. One notable partnership, established in 2024, linked AlgenScribe with the Max Delbrück Center for Molecular Medicine in Berlin to co‑develop enhanced gene‑editing tools, illustrating the company’s commitment to cross‑border scientific engagement.
As AlgenScribe progresses toward its next phases of development and fundraising, its combination of molecular innovation, targeted financing and collaborative partnerships positions it as an emerging player in the genomics and gene therapy technology landscape. With continued investment and scientific validation, the company aims to contribute meaningful advances to the treatment of genetic disease and the broader field of precision medicine.
